Stockscreener 앱 받기
17.94
2.97%
-0.55
시간 외 거래:
17.94
전일 마감가:
$18.49
열려 있는:
$18.5
하루 거래량:
9.65M
Relative Volume:
1.05
시가총액:
$9.26B
수익:
$11.24B
순이익/손실:
$-900.00M
주가수익비율:
-10.68
EPS:
-1.679
순현금흐름:
$323.00M
1주 성능:
-2.97%
1개월 성능:
+12.34%
6개월 성능:
-21.52%
1년 성능:
-41.24%
1일 변동 폭
$17.93
$18.64
1주일 범위
$17.89
$19.11
52주 변동 폭
$15.73
$32.68
박스터 인터내셔널 Stock (BAX) Company Profile
명칭
Baxter International Inc
전화
(224) 948-2000
주소
ONE BAXTER PARKWAY, DEERFIELD, IL
Compare BAX vs ISRG, BDX, MDLN, ALC, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
17.94 | 9.55B | 11.24B | -900.00M | 323.00M | -1.679 |
ISRG
Intuitive Surgical Inc
|
466.64 | 166.81B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
149.52 | 42.73B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
44.24 | 38.25B | 28.43B | 1.16B | 1.26B | 1.4457 |
ALC
Alcon Inc
|
75.40 | 37.05B | 10.40B | 980.00M | 1.61B | 1.9749 |
RMD
Resmed Inc
|
217.14 | 32.34B | 5.40B | 1.49B | 1.78B | 10.12 |
박스터 인터내셔널 Stock (BAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-31 | 다운그레이드 | Argus | Buy → Hold |
| 2025-08-04 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-08-01 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-02-26 | 재개 | Goldman | Buy |
| 2025-02-24 | 업그레이드 | Argus | Hold → Buy |
| 2025-02-20 | 재개 | Barclays | Overweight |
| 2024-07-15 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2024-05-30 | 개시 | Goldman | Neutral |
| 2024-05-10 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-03-29 | 개시 | UBS | Neutral |
| 2023-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-05 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-12-15 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2022-12-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-06-24 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-18 | 재확인 | KeyBanc Capital Markets | Overweight |
| 2022-02-18 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-18 | 재확인 | Raymond James | Outperform |
| 2022-02-18 | 재확인 | Stifel | Buy |
| 2022-02-18 | 재확인 | UBS | Neutral |
| 2022-02-18 | 재확인 | Wells Fargo | Overweight |
| 2022-02-11 | 개시 | Goldman | Neutral |
| 2022-01-07 | 재개 | Citigroup | Buy |
| 2022-01-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-09-13 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2021-09-03 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-05-25 | 개시 | Barclays | Equal Weight |
| 2021-01-29 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-06 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-12-15 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-10-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-09-04 | 다운그레이드 | Argus | Buy → Hold |
| 2020-06-24 | 개시 | Oppenheimer | Outperform |
| 2020-03-19 | 업그레이드 | Stifel | Hold → Buy |
| 2020-03-18 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-03-05 | 개시 | Citigroup | Neutral |
| 2020-02-13 | 개시 | Goldman | Buy |
| 2020-01-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-12-17 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-26 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2019-04-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-01-02 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-01-02 | 업그레이드 | Morgan Stanley | Underweight → Overweight |
| 2018-11-02 | 업그레이드 | Argus | Hold → Buy |
| 2018-10-16 | 개시 | Barclays | Underweight |
| 2018-05-17 | 재개 | Piper Jaffray | Overweight |
| 2018-02-06 | 재확인 | Citigroup | Neutral |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
모두보기
박스터 인터내셔널 주식(BAX)의 최신 뉴스
Baxter International Inc. stock outperforms competitors on strong trading day - MarketWatch
BlackRock Inc. (BAX) files 13G/A showing 33.1M shares (6.4%) - Stock Titan
Baxter discloses executive pay under new CEO and golden parachute for the last CEO - Medical Design & Outsourcing
Baxter Q1 Preview: Will Operational Headwinds Weigh on Results Again? - Yahoo Finance
Baxter International earnings preview: What to expect - MSN
Front Street Capital Management, Inc.'s Baxter International Inc(BAX) Holding History - GuruFocus
Baxter Showcases Recent Innovations at AORN Global Surgical Conference & Expo 2026 - Business Wire
Baxter International Inc. stock underperforms Friday when compared to competitors - MarketWatch
Baxter International unveils IV Verify to enhance IV labeling accuracy - MSN
Baxter International (BAX) Q4 earnings lag estimates - MSN
Baxter International Inc. stock underperforms Thursday when compared to competitors - MSN
Baxter International Inc. (BAX) Stock Price Today - MEXC Exchange
Analysts Estimate Baxter International (BAX) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Baxter International (BAX) Projected to Post Earnings on Thursday - MarketBeat
BAX (Baxter International Inc.) notches 5.7 percent Q4 2025 revenue growth as shares trade slightly higher despite EPS miss.Hedge Fund Inspired Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Baxter International Inc. stock outperforms competitors despite losses on the day - MarketWatch
Pzena shows 65.35M Baxter (NYSE: BAX) shares; 12.7% ownership - Stock Titan
Baxter International - Forbes
Baxter International Prepares Fiscal Q1 2026 Earnings Amid Profit Drop - HarianBasis.co
BAX Stock Price, Quote & Chart | BAXTER INTERNATIONAL INC (NYSE:BAX) - ChartMill
Smart Money is Buying Baxter International Inc. (BAX) - The Acquirer's Multiple
Baxter (BAX) Stock: Is It a Compelling Buy (Investor Interest) 2026-04-20Retail Flow - Cổng thông tin điện tử tỉnh Tây Ninh
Generic Injectables Market Major PlayersAstrazeneca, Baxter - openPR.com
Baxter International Inc. (BAX) Stock Analysis: Exploring an 18.20% Potential Upside Amidst Healthcare Growth - DirectorsTalk Interviews
Baxter International Earnings Preview: What to Expect - Yahoo Finance
Assessing Baxter International (BAX) Valuation After New Surgical Table And Smart Stretcher Unveiling - Sahm
Is It Too Late to Buy Baxter International Inc (BAX) After 3.1% Rally? GF Value Says Undervalued - GuruFocus
Is It Time To Reassess Baxter International (BAX) After A 35.9% One Year Share Price Slide - Yahoo Finance
Blood And Blood Components Market Is Booming So Rapidly | Baxter - openPR.com
Baxter International Inc. stock (US0673431090): Why does its hospital supply edge matter more now fo - AD HOC NEWS
Tiffany Zack joins Baxter as director of sustainability - Medical Buyer
Baxter International Inc stock (US0718131099): Is its medtech stability the real edge in uncertain m - AD HOC NEWS
Baxter Showcases Recent Innovations at AORN Global Surgical Conference and Expo 2026 - marketscreener.com
Baxter Welcomes Tiffany Zack as Director of Sustainability - Healthcare Digital
Baxter Highlights New Surgical and Patient Support Products - National Today
BAX Showcases Innovative Products at Global Surgical Conference - GuruFocus
Gap Down: Is Baxter International Inc a cyclical or defensive stockQuarterly Growth Report & Growth Focused Investment Plans - baoquankhu1.vn
Will Baxter’s New IV Automation Tool Subtly Reshape Its Patient Safety Edge and Valuation Story (BAX)? - simplywall.st
Short Squeeze: Is Baxter International Inc a cyclical or defensive stock2026 Macro Moves & Low Risk Growth Stock Ideas - baoquankhu1.vn
Baxter Launches Pilot Program for Therapy Animals in Healthcare Settings - respiratory-therapy.com
Baxter International Provides FY 2026 Earnings Guidance - National Today
Baxter (NYSE: BAX) exec holds 31K shares plus 25.9K options - Stock Titan
Baxter (NYSE: BAX) surgery chief lists common shares and option grants - Stock Titan
[Form 3] BAXTER INTERNATIONAL INC Initial Statement of Beneficial Ownership - Stock Titan
J&J Defends Blood-Clotting Powder IP From Baxter Attack - Law360
박스터 인터내셔널 (BAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.25%
자본화:
|
볼륨(24시간):